Levosimendan attenuates pulmonary vascular remodeling.

Area of Science:

• Cardiovascular Pharmacology
• Pulmonary Hypertension Research
• Vascular Biology

Background:

• Levosimendan is a calcium sensitizer used for acute right heart failure in pulmonary hypertension.
• It activates potassium channels, leading to pulmonary vasodilation.
• The study investigates levosimendan's potential to attenuate vascular remodeling in pulmonary hypertension.

Purpose of the Study:

• To determine if levosimendan attenuates pulmonary vascular remodeling in a rat model of pulmonary hypertension.
• To investigate the role of potassium channels in levosimendan's effects on pulmonary vasculature.
• To assess levosimendan's impact on pulmonary arterial smooth muscle cell proliferation and cardiac hypertrophy.

Main Methods:

• Rats with monocrotaline-induced pulmonary hypertension were treated with levosimendan, nicorandil, or levosimendan with a K(ATP) channel blocker (glibenclamide).
• Morphometric analyses, in vivo BrdU assays, and cell culture studies (PASMCs, HUVECs) were performed.
• Measurements included medial wall thickness, cell proliferation, cardiac hypertrophy, and inflammatory marker expression.

Main Results:

• Levosimendan and nicorandil attenuated pulmonary vascular medial wall thickening.
• Levosimendan reduced pulmonary arterial smooth muscle cell proliferation, an effect partially blocked by glibenclamide.
• Levosimendan decreased right ventricular hypertrophy independently of K(+) channels and demonstrated anti-inflammatory effects in endothelial cells.

Conclusions:

• Levosimendan attenuates pulmonary vascular remodeling through antiproliferative and anti-inflammatory mechanisms, likely involving cellular hyperpolarization.
• The drug also exerts a direct, K(+)-channel-independent inhibitory effect on cardiac hypertrophy.
• These findings suggest levosimendan has broader therapeutic potential in pulmonary hypertension beyond acute settings.